Kim Gallo Esthetics

FEBRUARY 27, 2024

The accessibility of tools and treatments prompts questions about their efficacy and safety, reminding us to trust professionals for guidance and comprehensive understanding. While there are at-home microneedling options available, it's best to seek professional treatment for optimal results and safety.

Skincare 296

Skincare Esthetician Skincare Routine Facial Massage 296

Dermatology Times

APRIL 4, 2025

Aaron Farberg, MD, discusses how, when prescribing therapies for pediatric patients, dermatologists prioritize long-term safety alongside efficacy. Topical Janus kinase (JAK) inhibitors have demonstrated a favorable safety profile compared with their oral counterparts, with minimal systemic absorption.

36

36

Alison Bladh

JANUARY 16, 2025

Safety and Precautions While saw palmetto is generally safe, there are a few important considerations to keep in mind: Potential Side Effects Mild digestive issues such as nausea, diarrhoea, or constipation may occur. Interactions Saw palmetto may interact with hormonal therapies, including birth control or hormone replacement therapy (HRT).

Extractions 98

Extractions Management Consultation Consultations 98

The Dermatology Digest

FEBRUARY 18, 2025

It was very encouraging in the ReNeu trial to see that Gomekli provided deep and durable responses, with a manageable safety profile that enabled patients to stay on therapy. Gomekli demonstrated a manageable safety and tolerability profile. Every treatment approval is hard-won, built on research, persistence, and partnership.

Networking 64

Networking Safety Innovations Management 64

Dermatology Times

JANUARY 9, 2024

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Safety 77

Safety Education Therapy Management 77

The Dermatology Digest

MARCH 10, 2025

” The safety profile was consistent with the known safety profile of tildrakizumab, and no serious adverse events related to ILUMYA treatment occurred in this clinical trial,the study showed. . ” The post Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO appeared first on The Dermatology Digest.

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

The Dermatology Digest

MARCH 8, 2025

The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% “PN is an intensely itchy skin disease, and for many years, there were no approved therapies, he says. The overall safety profile of ruxolitinib cream 1.5%

Safety 36

Safety Clinic Therapy Dermatology 36

AAAMS

MARCH 1, 2025

Improved Safety and Accuracy Automated systems and precision-guided technologies reduce the risk of human error, ensuring consistent and reliable outcomes. These benefits underscore why technology is now a cornerstone of modern aesthetic practices, appealing to patients who value efficiency, safety, and lasting value.

Technology 52

Technology Treatments Microneedling Innovations 52

Dermatology Times

OCTOBER 4, 2024

While researchers found both therapies effective in long-term use, they stated secukinumab showed quicker improvements in QoL.

Therapy 45

Therapy Safety 45

The Dermatology Digest

DECEMBER 11, 2024

Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported. The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe AD.

Safety 36

Safety Dermatitis Therapy Dermatology 36

The Dermatology Digest

MARCH 17, 2025

The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated. Both studies include a 12-week double-blind, placebo-controlled treatment period, followed by a 42-week extension period and 30-day safety follow-up. 75mg: 40.6% 75mg: 42.3%

Safety 36

Safety Document Clinic Therapy 36

Dermatology Times

JULY 4, 2024

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

Safety 36

Safety Therapy Treatments 36

Dermatology Times

MARCH 14, 2025

Panelists discuss how JAK inhibitors demonstrate significant efficacy in treating atopic dermatitis while examining their safety profiles and optimal positioning within the therapeutic landscape.

Safety 36

Safety Dermatitis Therapy 36

Dermatology Times

NOVEMBER 1, 2024

VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.

Safety 57

Safety Therapy 57

The Dermatology Digest

DECEMBER 4, 2024

Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients. The estimated incidence of PM/DM is approximately 5 to 22 cases per 100,000 individuals.

Treatments 36

Treatments Office Therapy Clinic 36

Alison Bladh

JANUARY 1, 2025

Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Dermatologic Therapy. Platelet-Rich Plasma Therapy for Hair Growth: A Systematic Review. Microblading: Safety and Efficacy in Eyebrow Enhancement.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

The Dermatology Digest

FEBRUARY 25, 2025

This announcement follows the successful completion of a Phase I clinical trial involving 40 healthy volunteers, where ruxoprubart demonstrated promising results and a clean safety profile, with no serious adverse events reported.

Safety 36

Safety Therapy Clinic Dermatology 36

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

Dermatology Times

JANUARY 8, 2024

Systemic corticosteroids are often used as primary therapy for PG, but alternatives should be considered for their favorable safety profile.

Clinic 78

Clinic Management Safety Treatments 78

Aesthetics Exposed

MARCH 22, 2019

Lasers and light therapies are among the most commonly used devices in the esthetic industry. There are three main types of light therapy used in esthetics: LED, IPL and lasers. Build Your Light Knowledge The spectrum of light therapy treatments available is pretty large; this is just a quick breakdown of IPL and laser.

Hair Removal 195

Hair Removal Esthetics Collagen Rosacea 195

The Dermatology Digest

MARCH 17, 2025

The multi-center, randomized, double-blind, placebo-controlled, proof-of-concept trial is designed to evaluate the safety and efficacy of EVO301 in approximately 60 adult patients with moderate-to-severe AD. EASI, the Eczema Area and Severity Index score, isa tool used to measure the extent and severity of atopic dermatitis.

Dermatitis 36

Dermatitis Eczema Injections Tools 36

US Dermatologt Partners

JUNE 1, 2024

In the ever-evolving landscape of psoriasis treatment, oral therapies continue to play a crucial role. 2 Newer Generation Oral Therapies “We live in an exciting time because we’ve got new topical therapies, multiple oral therapies, and obviously, an array of biologic agents and patient preferences change,” Lockshin said.

Therapy 41

Therapy Injections Safety Management 41

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. At week 24, 22.7% of patients in the higher dose group achieved this endpoint, a 14.4%

Dermatitis 36

Dermatitis Safety Office Eczema 36

Dermatology Times

MARCH 10, 2025

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Dermatitis 53

Dermatitis Therapy Safety Treatments 53

Dermatology Times

JUNE 4, 2024

This week’s collection of the latest dermatologic studies includes the use of digital communication for patients with hidradenitis suppurativa (HS), rituximab for pediatric patients with pemphigus, a case report of primary oral extramammary Paget disease, and the efficacy and safety of LAight therapy for HS.

Safety 69

Safety Therapy Dermatology 69

The Dermatology Digest

AUGUST 20, 2024

Food and Drug Administration (FDA) approved apremilast for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. The adverse events were consistent with the known safety profile of Otezla in adult patients.

Safety 74

Safety Injections Therapy Treatments 74

Dermatology Times

MARCH 14, 2024

A panel of experts discusses unique needs of patients with skin of color, look at long-term safety and efficacy of emerging oral treatments, and delve into combining topicals with systemic therapies.

Management 74

Management Safety Therapy Treatments 74

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. The new topical therapies constitute the lower rungs of the therapeutic ladder and can be used for both exacerbations and maintenance.

Treatments 77

Treatments Dermatitis Therapy Medical 77

Dermatology Times

AUGUST 8, 2024

Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.

Safety 36

Safety Treatments Therapy 36

New Age Spa Institute

DECEMBER 18, 2024

Also known as NASI , this private beauty school in Des Plaines, IL offers training programs for professional licensing in esthetics, massage therapy, makeup, and more. Certifications are targeted programs designed to enhance your knowledge and skills in specific areas of esthetics, cosmetology, or massage therapy. </p>

Medical 52

Medical Esthetics Legal Continuing Education 52

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

The Dermatology Digest

MARCH 3, 2025

We are very pleased that our patients, from birth, will have a simple, topical treatment that promotes durable wound closure, something that until now has been beyond the reach of any therapy, adds Christine Bodemer, MD, PhD, Professor and Head of the Department of Dermatology at the Necker Enfants Malades Hospital in Paris.

Therapy 36

Therapy Clinic Hospital Dermatology 36

New Age Spa Institute

NOVEMBER 20, 2024

Licenses like those for esthetics, cosmetology , and massage therapy give professionals the legal right to practice their craft and offer services to the public. Choosing Between Esthetics, Cosmetology & Massage Therapy One of the most common questions we hear is, “ What’s the difference between an esthetician and a cosmetologist?

Esthetics 52

Esthetics Therapy Continuing Education Continuous Education 52

The Dermatology Digest

JULY 1, 2024

PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis.

Portfolios 74

Portfolios Safety Clinic Injections 74

The Dermatology Digest

FEBRUARY 10, 2025

The submission will be supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients. CORDStrom is a patent-pending, off-the-shelf, advanced mesenchymal stromal cell (MSC) platform developed to treat complex inflammatory diseases.

Hospital 36

Hospital Sustainability Therapy Marketing 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Active Ingredients in Pigmentation Therapy In-office treatments are complemented by topical agents that help maintain results and prevent new pigmentation. Sequence Treatments for Safety: Estheticians can schedule less invasive treatments first and reserve higher-intensity therapies for later sessions to reduce skin sensitization.

Chemical Peels 52

Chemical Peels Vitamin C Hyperpigmentation Microneedling 52

Online Laser Training

OCTOBER 11, 2019

Godfrey will make his ‘Core of knowledge’ laser and IPL safety courses available to post-graduates and assist in collaborative efforts to introduce new specialist courses in cutaneous light-based therapy to the department. Dr Godfrey Town has been appointed Senior Research Fellow Ph.D.,

Hospital 78

Hospital Safety Training Clinic 78